954 related articles for article (PubMed ID: 29070816)
1. Resistance to checkpoint blockade therapy through inactivation of antigen presentation.
Sade-Feldman M; Jiao YJ; Chen JH; Rooney MS; Barzily-Rokni M; Eliane JP; Bjorgaard SL; Hammond MR; Vitzthum H; Blackmon SM; Frederick DT; Hazar-Rethinam M; Nadres BA; Van Seventer EE; Shukla SA; Yizhak K; Ray JP; Rosebrock D; Livitz D; Adalsteinsson V; Getz G; Duncan LM; Li B; Corcoran RB; Lawrence DP; Stemmer-Rachamimov A; Boland GM; Landau DA; Flaherty KT; Sullivan RJ; Hacohen N
Nat Commun; 2017 Oct; 8(1):1136. PubMed ID: 29070816
[TBL] [Abstract][Full Text] [Related]
2. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
Liu D; Schilling B; Liu D; Sucker A; Livingstone E; Jerby-Arnon L; Zimmer L; Gutzmer R; Satzger I; Loquai C; Grabbe S; Vokes N; Margolis CA; Conway J; He MX; Elmarakeby H; Dietlein F; Miao D; Tracy A; Gogas H; Goldinger SM; Utikal J; Blank CU; Rauschenberg R; von Bubnoff D; Krackhardt A; Weide B; Haferkamp S; Kiecker F; Izar B; Garraway L; Regev A; Flaherty K; Paschen A; Van Allen EM; Schadendorf D
Nat Med; 2019 Dec; 25(12):1916-1927. PubMed ID: 31792460
[TBL] [Abstract][Full Text] [Related]
3. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Zaretsky JM; Garcia-Diaz A; Shin DS; Escuin-Ordinas H; Hugo W; Hu-Lieskovan S; Torrejon DY; Abril-Rodriguez G; Sandoval S; Barthly L; Saco J; Homet Moreno B; Mezzadra R; Chmielowski B; Ruchalski K; Shintaku IP; Sanchez PJ; Puig-Saus C; Cherry G; Seja E; Kong X; Pang J; Berent-Maoz B; Comin-Anduix B; Graeber TG; Tumeh PC; Schumacher TN; Lo RS; Ribas A
N Engl J Med; 2016 Sep; 375(9):819-29. PubMed ID: 27433843
[TBL] [Abstract][Full Text] [Related]
4. Indicators of responsiveness to immune checkpoint inhibitors.
Shields BD; Mahmoud F; Taylor EM; Byrum SD; Sengupta D; Koss B; Baldini G; Ransom S; Cline K; Mackintosh SG; Edmondson RD; Shalin S; Tackett AJ
Sci Rep; 2017 Apr; 7(1):807. PubMed ID: 28400597
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
Simeone E; Ascierto PA
J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic control of
Wang MM; Koskela SA; Mehmood A; Langguth M; Maranou E; Figueiredo CR
Front Immunol; 2023; 14():1152228. PubMed ID: 37077920
[TBL] [Abstract][Full Text] [Related]
7. [Immune checkpoint antibodies increase survival in patients with metastatic melanoma].
Fløe LE; Svane IM; Bastholt L; Schmidt H
Ugeskr Laeger; 2016 Aug; 178(33):. PubMed ID: 27550784
[TBL] [Abstract][Full Text] [Related]
8. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.
Paschen A; Méndez RM; Jimenez P; Sucker A; Ruiz-Cabello F; Song M; Garrido F; Schadendorf D
Int J Cancer; 2003 Mar; 103(6):759-67. PubMed ID: 12516095
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
[TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
11. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
Gao J; Shi LZ; Zhao H; Chen J; Xiong L; He Q; Chen T; Roszik J; Bernatchez C; Woodman SE; Chen PL; Hwu P; Allison JP; Futreal A; Wargo JA; Sharma P
Cell; 2016 Oct; 167(2):397-404.e9. PubMed ID: 27667683
[TBL] [Abstract][Full Text] [Related]
12. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM
Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
[TBL] [Abstract][Full Text] [Related]
14. Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma.
Zhao B; Zhao H; Zhao J
Int J Cancer; 2019 Jan; 144(1):169-177. PubMed ID: 30121946
[TBL] [Abstract][Full Text] [Related]
15. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Anagnostou V; Smith KN; Forde PM; Niknafs N; Bhattacharya R; White J; Zhang T; Adleff V; Phallen J; Wali N; Hruban C; Guthrie VB; Rodgers K; Naidoo J; Kang H; Sharfman W; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Zahnow CA; Baylin SB; Scharpf RB; Brahmer JR; Karchin R; Pardoll DM; Velculescu VE
Cancer Discov; 2017 Mar; 7(3):264-276. PubMed ID: 28031159
[TBL] [Abstract][Full Text] [Related]
16. Therapy of metastatic malignant melanoma: on the way to individualized disease control.
Vogt T
Adv Exp Med Biol; 2014; 810():272-81. PubMed ID: 25207371
[TBL] [Abstract][Full Text] [Related]
17. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
18. Antitumor Immune Responses in B2M-Deficient Cancers.
Torrejon DY; Galvez M; Abril-Rodriguez G; Campbell KM; Medina E; Vega-Crespo A; Kalbasi A; Comin-Anduix B; Ribas A
Cancer Immunol Res; 2023 Dec; 11(12):1642-1655. PubMed ID: 37801341
[TBL] [Abstract][Full Text] [Related]
19. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
20. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.
Budczies J; Bockmayr M; Klauschen F; Endris V; Fröhling S; Schirmacher P; Denkert C; Stenzinger A
Genes Chromosomes Cancer; 2017 Aug; 56(8):651-659. PubMed ID: 28466543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]